Search   
MSDS  : Insulin protamine zinc
CAS  : 9004-17-5
SYNONYMS  : * Depo-insulin * Deposulin * Insulin retard RI * Insulin zinc protaminate * Insulin zinc protamine * Insulyl-retard * I.P.Z. * Isophane insulin * Isophane insulin suspension * NPH insulin * NPH 50 insulin * Protamine zinc insulin * Protamine zinc insulin injection * Protamine zinc insulin suspension * Zinc protamine insulin
*** CHEMICAL IDENTIFICATION ***

RTECS NUMBER : NM8912800
CHEMICAL NAME : Insulin protamine zinc
CAS REGISTRY NUMBER : 9004-17-5
LAST UPDATED : 199706
DATA ITEMS CITED : 6
COMPOUND DESCRIPTOR : Drug
Reproductive Effector
Hormone
SYNONYMS/TRADE NAMES :
* Depo-insulin
* Deposulin
* Insulin retard RI
* Insulin zinc protaminate
* Insulin zinc protamine
* Insulyl-retard
* I.P.Z.
* Isophane insulin
* Isophane insulin suspension
* NPH insulin
* NPH 50 insulin
* Protamine zinc insulin
* Protamine zinc insulin injection
* Protamine zinc insulin suspension
* Zinc protamine insulin

*** HEALTH HAZARD DATA ***

** ACUTE TOXICITY DATA **

TYPE OF TEST : LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE : Intraperitoneal
SPECIES OBSERVED : Rodent - rat
DOSE/DURATION : 830 ug/kg
TOXIC EFFECTS :
Behavioral - ataxia
Endocrine - hypoglycemia
Nutritional and Gross Metabolic - body temperature decrease
REFERENCE :
TXAPA9 Toxicology and Applied Pharmacology. (Academic Press, Inc., 1 E.
First St., Duluth, MN 55802) V.1- 1959- Volume(issue)/page/year:
4,631,1962

TYPE OF TEST : LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE : Subcutaneous
SPECIES OBSERVED : Rodent - mouse
DOSE/DURATION : 195 iu/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
AIPTAK Archives Internationales de Pharmacodynamie et de Therapie. (Heymans
Institute of Pharmacology, De Pintelaan 185, B-9000 Ghent, Belgium) V.4-
1898- Volume(issue)/page/year: 153,379,1965

** REPRODUCTIVE DATA **

TYPE OF TEST : TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE : Subcutaneous
SPECIES OBSERVED : Rodent - rat
DOSE : 1458 ug/kg
SEX/DURATION : female 15-21 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Newborn - stillbirth
REFERENCE :
DIAEAZ Diabetes. (American Diabetes Assoc., 2 Park Ave., New York, NY
10016) V.1- 1952- Volume(issue)/page/year: 13,44,1964

TYPE OF TEST : TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE : Intramuscular
SPECIES OBSERVED : Rodent - rat
DOSE : 42 iu/kg
SEX/DURATION : female 14-20 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Newborn - biochemical and metabolic
Reproductive - Effects on Newborn - behavioral
Reproductive - Effects on Newborn - other postnatal measures or effects
REFERENCE :
DBRRDB Developmental Brain Research. (Elsevier Science Pub. B.V., POB 211,
1000 AE Amsterdam, Netherlands) V.1- 1981- Volume(issue)/page/year:
88,127,1995

TYPE OF TEST : TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE : Intraperitoneal
SPECIES OBSERVED : Rodent - mouse
DOSE : 167 ug/kg
SEX/DURATION : female 8 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - Central Nervous System
Reproductive - Specific Developmental Abnormalities - musculoskeletal system
REFERENCE :
ANREAK Anatomical Record. (Alan R. Liss, Inc., 41 E. 11th St., New York, NY
10003) V.1- 1906/08- Volume(issue)/page/year: 124,441,1956

*** NIOSH STANDARDS DEVELOPMENT AND SURVEILLANCE DATA ***

NIOSH OCCUPATIONAL EXPOSURE SURVEY DATA :
NOES - National Occupational Exposure Survey (1983)
NOES Hazard Code - X6062
No. of Facilities: 7 (estimated)
No. of Industries: 1
No. of Occupations: 2
No. of Employees: 628 (estimated)
No. of Female Employees: 314 (estimated)


*** END OF RECORD ***
Search More   
ALL Chemical Property And Toxicity Analysis PAGES IN THIS GROUP
NAMECAS
D-myo-Inositol,O-2,6-diamino-2,6-dideoxy-alpha-D-glucopyranosyl-(1-4)-O-(O-2,6-diamino-2, 6-dideoxy-beta-L-idopyranosyl-(1-3)-beta-D-ribofuranosyl-(1-5))-3-amino-2,3- dideoxy- 91421-97-5
D-myo-Inositol,O-2,3-diamino-dideoxy-alpha-D-gucopyranosyl-(1-1)-O-(2,6-diamino-2,3,4,6-tetradeoxy-alpha-D-erythro-hexopyranosyl(1-3)-2,4-diamino-6-((4-amino-2-hy droxy-1-oxobutyl)amino)-2,4,5,6-tetradeoxy-, (S)- 161822-04-4
D-myo-Inositol,O-2,6-diamino-2,6-dideoxy-alpha-D-glucopyranosyl-(1-4)-O-(beta-D-ribofuranosyl-(1-5))-1,3-diamino-1,3-dideoxy- 52248-05-2
epi-Inositol,2,3-dideoxy-2-((2-hydroxy-1-(hydroxymethyl)ethyl)amino)-4-C-(hydroxymethyl )- 112653-29-9
D-chiro-Inositol,1,5-dideoxy-5-(hydroxymethyl)-1-((4,5,6-trihydroxy-3-(hydroxymethyl)-2- cyclohexen-1-yl)amino)-,(1S-(1-alpha,4-alpha,5-beta,6-alpha))- 39318-73-5
2-Indolinone,3-(3-dimethylaminopropyl)-1-methyl-3-phenyl-,hydrochloride 10565-90-9
D-chiro-Inositol,O-alpha-D-glucopyranosyl-(1-4)-O-beta-D-glucopyranosyl-(1-3)-1,5,6-trideoxy-5-(hydroxymethyl)-1-((4,5,6-trihydroxy-3-(hydroxymethyl)-2-cycloh exen-1-yl)amino)-,(1S-(1-alpha,4-alpha,5-beta,6-alpha))- 12650-71-4
Inositol,hexakis(2-(p-chlorophenoxy)-2-methylpropionate), myo- 14496-74-3
Inositol, hexakis(dihydrogen phosphate), myo- 83-86-3
Inositol, hexakis(dihydrogen phosphate), calciummagnesium salt, myo- 3615-82-5
Inositol, hexakis(dihydrogen phosphate) sodium salt,myo- 14306-25-3
Inositol, hexakis(disodium phosphate), hydrate (135) 14306-25-3
myo-Inositol, hexakis(5-fluoro-3-pyridinecarboxylate) 23763-98-6
myo-Inositol, hexakis(hydrogen sulfate), hexasodiumsalt 70701-62-1
Inositol, hexanicotinate, myo- 6556-11-2
meso-Inositol, hexanitrate 6556-11-2
2-Indolinone, 3,3-bis(2-hydroxypropyl)-1-phenyl- 20870-64-8
2-Indolinone,3-(3-(dimethylamino)propyl)-1-(methyl-2-thenylamino)-3-phenyl- 33391-50-3
scyllo-Inositol, hexanitrate 33391-50-3
D-chiro-Inositol,5-(hydroxymethyl)-1,5,6-trideoxy-1-((4,5,6-trihydroxy-3-(hydroxymethyl)-2- cyclohexen-1-yl)amino)-,(1S-(1-alpha,4-alpha,5-beta,6-alpha))- 38665-10-0
D-chiro-Inositol,1,5,6-trideoxy-3-O-beta-D-glucopyranosyl-5-(hydroxymethyl)-1-((4,5,6-trihydroxy-3-(hydroxymethyl)-2-cyclohexen-1-yl)amino)-, (1S-(1-alpha,4-alpha,5-beta, 6-alpha))- 37248-47-8
InstanetSUBSTANCE DEFINITION :Consists of butylglycol and a small quantity of ethanolREFERENCE :HUTODJ Human Toxicology. (Macmillan Press Ltd., Houndmills, Basingstoke,Hants., RG 21 2XS, UK) V.1- 1981- Volume(issue)/page/year: 8,243,1989 37248-47-8
Insularinium, 2,2'-dimethyl-, diiodide 32434-10-9
Insulin 9004-10-8
Insulin, pyrolyzate 9004-10-8
Insulin (dog) 12584-58-6
Insulin (human), 28b-L-lysine-29b-L-proline- 133107-64-9
Insulin-like growth factor I 67763-96-6
2-Indolinone,1,5-dimethyl-3-(5-phenyl-1,3,4-oxadiazol-2-ylimino)- 84640-78-8
Insulin-like growth factor I (human) 68562-41-4
Insulin-like growth factor II 67763-97-7
Insulin protamine zinc 9004-17-5
Insulin sensitizer enhancer, S18277 9004-17-5
Insulin zinc 8049-62-5
Integerrimine 480-79-5
Interferon-alpha 480-79-5
Interferon-alpha-2 (human leucocyte clone pM21protein moiety reduced) 98530-12-2
Interferon-alpha-2 (human leucocyte protein moietyreduced) 75432-97-2
Interferon-alpha-4 (human leucocyte) 75432-97-2
2-Indolinone,3,3-diphenyl-5-methoxy-1-(piperidinomethyl)- 81252-99-5
Interferon-beta, (human)SUBSTANCE DEFINITION :A polypeptide consisting of 166 amino acidsREFERENCE :KSRNAM Kiso to Rinsho. Clinical Report. (Yubunsha Co., Ltd., 1-5, KandaSuda-Cho, Chiyoda-ku, KS Bldg., Tokyo 101, Japan) V.1- 1960- 81252-99-5
Interferon A (human myeloblastoid KG-1 protein moietyreduced) 76543-88-9
Interferon-gamma (human lymphocyte protein moietyreduced) 82115-62-6
Interferon-gamma, OH-6000 82115-62-6
Interferons 9008-11-1
Interleukin 1SUBSTANCE DEFINITION :Purified interleukin 1 derived from human monocytesREFERENCE :CNREA8 Cancer Research. (Public Ledger Building, Suit 816, 6th & ChestnutSts., Philadelphia, PA 19106) V.1- 1941- Volume(issue)/page/year:47,5612,1987 9008-11-1
Interleukin-1-alpha 9008-11-1
Interleukin-1-beta 9008-11-1
Interleukin 2 (human clone pTG853 protein moietyreduced) 94218-75-4
Interleukin 2 (human clone pTIL2-21a protein moiety) 94218-72-1

Free MSDS Search ( Providing 250,000+ Material Properties )
Chemcas.com| Ads link:todaystock.net